Cara Therapeutics | CARA - Current Assets


Cara Therapeutics reported $25.33M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
Cara Therapeutics USD 25.33M 6.21M Mar/2026
Cassava Sciences USD 87.96M 9.74M Mar/2026
Chugai Pharma JPY 1.7T 164.75B Jun/2026
Cipla INR 241.47B 7.71B Mar/2026
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 137.28M 10.74M Mar/2026
CSL USD 11.85B 1000K Dec/2025
Grifols EUR 5.96B 316.31M Dec/2025
Halozyme Therapeutics USD 1B 177.83M Mar/2026
J&J USD 59.77B 601M Jun/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Pacira USD 514.96M 33.01M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
RedHill Biopharma USD 6.53M 6.03M Dec/2025
Supernus Pharmaceuticals USD 723.5M 8.08M Jun/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025